CERo Therapeutics announces $5 million public offering for cancer treatment development

From GlobeNewswire: 2025-02-05 20:00:00

CERo Therapeutics Holdings, Inc. announces a public offering of 2,551,020 shares of common stock at $1.96 per share, with gross proceeds expected to be around $5 million. The funds will be used for clinical programs and general corporate purposes. The offering is expected to close on February 7, 2025, subject to customary conditions. A.G.P./Alliance Global Partners is the sole placement agent, and Jones serves as financial advisor for the offering. The company’s novel cellular immunotherapy platform aims to develop Chimeric Engulfment Receptor T cells for cancer treatment, with clinical trials for lead product candidate CER-1236 set to begin in 2024.

This press release contains forward-looking statements about the expected closing date and use of proceeds from the offering. Risks associated with these statements are detailed in CERo’s filings with the Securities and Exchange Commission. The company’s management makes projections based on beliefs and available information. Actual results may differ, and new risk factors may emerge over time. CERo does not guarantee the performance implied by forward-looking statements and is not obligated to update or revise them. Contact CEO Chris Ehrlich for more information.



Read more at GlobeNewswire: CERo Therapeutics Announces $5 Million Public Offering